Project Grant R21TR006197
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $462K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, awarded Icahn School of Medicine at Mount Sinai a $168,000 Project Grant commencing May 1, 2026, and concluding April 30, 2028. This research initiative focuses on developing and characterizing a three-dimensional lung organoid model to investigate early cystic fibrosis (CF) lung disease pathogenesis and the role of cystic fibrosis transmembrane conductance regulator (CFTR) protein in...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $730,268 on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a versatile paired prime editing toolkit for correcting Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutations. The grant supports a research initiative extending through May 31, 2030, focused on creating a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $1,175,924 under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026 through January 31, 2033. This research initiative, titled "Hemogenic Mesoderm Heterogeneity, Regulation, and Function," focuses on understanding the molecular and transcriptional mechanisms underlying embryonic hematopoietic...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $489,500 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective June 5, 2025, through May 31, 2027. The award funds research and development activities focused on translating the compound REPSOX and its analogs toward clinical application as a prophylactic intervention for Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM),...
- Grant Award Summary Brigham & Women's Hospital, in collaboration with Boston Children's Hospital and Harvard Medical School, received an $800,962 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion by June 30, 2030. The award supports research investigating endothelial inflammation, C-terminal Src kinase (CSK) dysregulation, and fibrosis in early pulmonary...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $489,500 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective September 3, 2025, through September 2, 2027. This grant funds the development of patient-centric clinical outcome measures for Multiple Sulfatase Deficiency (MSD), an ultra-rare, fatal neurodegenerative disorder with emerging therapeutic options including AAV-based gene...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $713,421 Project Grant to Icahn School of Medicine at Mount Sinai on September 3, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the regulation of thin filament architecture by CAP2 (Cyclase-Associated Protein 2) in health and myopathy. The research aims to elucidate the physiological mechanisms linking aberrant actin-thin filament assembly to...
- Federal Project Grant Summary Massachusetts General Hospital received a $1.52M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of June 30, 2029. The award funds development and clinical validation of mechanomicroscopy, an innovative endoscopic imaging platform designed to enable transbronchial assessment of pulmonary hypertension (PH) due to lung disease....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a $514,484 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 24, 2025, for research investigating the role of kynurenine pathway metabolism in pulmonary arterial hypertension (PAH). The research will be conducted through June 30, 2030, at Johns Hopkins' Maryland facilities. The project delivers basic and translational research services focused on...
- Federal Project Grant Award Summary SNJ Pharma Inc. received a $499,882 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 15, 2025, with completion targeted by August 31, 2026. The award funds the development and evaluation of rHTRA1 (recombinant high-temperature requirement A1), a novel plasmin-independent thrombolytic agent designed to treat pulmonary embolism (PE). This...